Marker Therapeutics, Inc. MRKR Q2 2025 earnings
Reported August 14, 2025 · Before market open
Revenue$861.2KBeat by $430.6K
EPS-$0.29Beat by $0.01
Revenue estimate$430.6K
EPS estimate-$0.30
Next report
Aug 13, 2026 (In 2 weeks)Revenue estimate$682.1K
EPS estimate-$0.25
Versus estimates
Revenue
Q4 2025$1.1MBeat by $417.9KQ3 2025$1.2MBeat by $509.9K
Q2 2025$861.2KBeat by $430.6K
Q1 2025$349.1KBeat by $174.6KQ4 2024$2.3MBeat by $1.0MDiluted EPS
Ask the moment Marker Therapeutics, Inc. reports.
Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.
Connect your AI
Claude
Questions, answered.
- When did Marker Therapeutics, Inc. report Q2 2025 earnings?
- Marker Therapeutics, Inc. (MRKR) reported Q2 2025 earnings on August 14, 2025 before market open.
- What were Marker Therapeutics, Inc.'s Q2 2025 revenue and EPS?
- Marker Therapeutics, Inc. reported revenue of $861.2K and eps of $-0.29 for Q2 2025.
- Did Marker Therapeutics, Inc. beat estimates in Q2 2025?
- Revenue beat the consensus estimate of $430.6K by $430.6K. EPS beat the consensus estimate of $-0.30 by $0.01.
- How did Marker Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 26.3% from $1.2M a year earlier and eps grew 0.0% from $-0.29.
- Where can I find Marker Therapeutics, Inc.'s Q2 2025 SEC filings?
- You can read the 10-Q periodic report (0001410578-25-001826) directly on SEC EDGAR. The filing index links above go to sec.gov.